secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001683168-25-004759
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort
--------------------------------------------------------------------------------

- Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.
- No dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent reactions in fourth cohort (5 patients).
- To date, 15 patients treated; pathological complete response (100% clearance) seen in 4 of 9 cSCC patients from prior cohorts.
- Enrollment in final cohort expected to complete in Q3 2025.
- PH-762 is an intratumoral siRNA targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825004759/0001683168-25-004759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825004759/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-004759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer